Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
Scientific presentation

Myeloma Matters: Advancing Research and Therapy Development with Single-cell DNA + Protein Multi-Omics


Todd Druley, MD, PhD
Adam Sciambi, PhD

Description

Multiple myeloma is a complex form of plasma cell cancer that is currently untreatable. There are approximately 200,000 new diagnoses each year globally, with a 100% relapse rate and 54% five-year overall survival rate. In spite of significant advancements in treating blood-related cancers, these diseases continue to be a substantial cause of illness and death worldwide.

In this presentation, Dr. Todd Druley, MD, Ph.D., Chief Medical Officer of Mission Bio, and Co-Founder and Chief Technology Officer Dr. Adam Sciambi, Ph.D:

• Discuss the clinical impact and horizon of multiple myeloma therapies
• Present a novel approach to multiple myeloma therapeutic development by correlating SNVs, CNVs, and surface epitopes for clonal profiling
• Share clinical data generated by researchers from The Cancer Research Center of Toulouse IUCT-Oncopole and Genentech



VIEW


Scientific presentation
Single-cell Multi-omics for Discovery, Translational, and Clinical Development
Gema Fuerte, PhD
World CDx Europe (2024)
Scientific presentation
Confidently Validate Cancer Models for Precision Medicine
Dr. Robert Bowman
Divya Rao
(2024)
Scientific presentation
Unveiling Cellular Complexity: Why & How to Integrate Single-Cell DNA Multi-omics
Brittany Enzmann, PhD
Divya Rao, PhD
Adam Sciambi, PhD
(2024)
Scientific presentation
Unleashing the Potential of CRISPR & Navigating Heterogeneity in Genome Editing Outcomes
Travis Hardcastle, Synthego
Brittany Enzmann, Mission Bio
(2024)
REQUEST QUOTE